GARDASIL®: Prophylactic human papillomavirus vaccine development - From bench top to bed-side
Clinical Pharmacology and Therapeutics, ISSN: 0009-9236, Vol: 81, Issue: 2, Page: 259-264
2007
- 108Citations
- 156Captures
- 3Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations108
- Citation Indexes108
- 108
- CrossRef99
- Captures156
- Readers156
- 156
- Mentions3
- References3
- Wikipedia3
Article Description
GARDASIL® (Merck, Whitehouse Station, NJ) is a non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid proteins of human papillomavirus (HPV) types 6, 11, 16, and 18. GARDASIL® is the first vaccine approved for use in women aged 9-26 years for the prevention of cervical cancer and genital warts, as well as vulvar and vaginal precancerous lesions. This report describes some of the key preclinical efforts, achievements in pharmaceutical development, in vivo animal evaluation, and clinical trial data. © 2007 American Society for Clinical Pharmacology and Therapeutics.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33846647567&origin=inward; http://dx.doi.org/10.1038/sj.clpt.6100055; http://www.ncbi.nlm.nih.gov/pubmed/17259949; http://doi.wiley.com/10.1038/sj.clpt.6100055; http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100055/abstract?systemMessage=Wiley+Online+Library+will+be+unavailable+for+up+to+3+hours+on+Saturday+19th+March+2016+from++11%3A00-14%3A00+GMT+%2F+07%3A00-10%3A00+EDT+%2F+19%3A00-22%3A00+SGT+for+essential+maintenance.++Apologies+for+the+inconvenience.
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know